MX2022010006A - Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo. - Google Patents

Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo.

Info

Publication number
MX2022010006A
MX2022010006A MX2022010006A MX2022010006A MX2022010006A MX 2022010006 A MX2022010006 A MX 2022010006A MX 2022010006 A MX2022010006 A MX 2022010006A MX 2022010006 A MX2022010006 A MX 2022010006A MX 2022010006 A MX2022010006 A MX 2022010006A
Authority
MX
Mexico
Prior art keywords
pridopidine
combination
active agent
combination therapy
amyotrophic lateral
Prior art date
Application number
MX2022010006A
Other languages
English (en)
Inventor
Michal Geva
Michael Hayden
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/789,564 external-priority patent/US11406625B2/en
Priority claimed from US17/076,069 external-priority patent/US20210030734A1/en
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of MX2022010006A publication Critical patent/MX2022010006A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporciona un método para tratar a un sujeto humano afectado por ELA mediante la administración al sujeto de una cantidad terapéuticamente eficaz de pridopidina o una sal farmacéuticamente aceptable de la misma en combinación con fenilbutirato de sodio (PB), ácido tauroursodesoxicólico, combinación de fenilbutirato de sodio (PB)/ácido tauroursodesoxicólico (es decir, AMX0035), Zilucoplan, Verdiperstat, oro nanocristalino CNM-Au8, SLS-005 (trehalosa), IC14 o una combinación de los mismos como terapia combinada o complementaria.
MX2022010006A 2020-02-13 2021-02-13 Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo. MX2022010006A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/789,564 US11406625B2 (en) 2017-08-14 2020-02-13 Method of treating amyotrophic lateral sclerosis with pridopidine
US17/076,069 US20210030734A1 (en) 2017-08-14 2020-10-21 Method of treating amyotrophic lateral sclerosis with pridopidine
PCT/IL2021/050172 WO2021161319A1 (en) 2020-02-13 2021-02-13 Combination therapy for treating amyotrophic lateral using pridopidine and another active agent

Publications (1)

Publication Number Publication Date
MX2022010006A true MX2022010006A (es) 2022-09-19

Family

ID=77291775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010006A MX2022010006A (es) 2020-02-13 2021-02-13 Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo.

Country Status (8)

Country Link
EP (1) EP4103179A4 (es)
JP (1) JP2023518670A (es)
CN (1) CN115103676A (es)
AU (1) AU2021219072A1 (es)
CA (1) CA3167214A1 (es)
IL (1) IL295562A (es)
MX (1) MX2022010006A (es)
WO (1) WO2021161319A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024095118A1 (en) * 2022-10-31 2024-05-10 Novartis Ag Dosing regimen of a csf-1r inhibitor for use in the treatment of amyotrophic lateral sclerosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133884A2 (en) * 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
EP2422787A1 (en) * 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
US9872865B2 (en) * 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
JP6837835B2 (ja) * 2013-05-07 2021-03-03 バイオ・ブラスト・ファーマ・リミテッドＢｉｏ Ｂｌａｓｔ Ｐｈａｒｍａ Ｌｔｄ． トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
PL3016654T3 (pl) * 2013-07-01 2019-02-28 Bruschettini S.R.L. Kwas tauroursodeoksycholowy (TUDCA) do zastosowania w leczeniu zaburzeń neurodegeneracyjnych
US20200148780A1 (en) * 2017-04-21 2020-05-14 Implicit Bioscience Pty Ltd Cd 14 antagonist antibodies for treating neurodegenerative diseases
EP3668509B1 (en) * 2017-08-14 2022-11-16 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine

Also Published As

Publication number Publication date
CA3167214A1 (en) 2021-08-19
IL295562A (en) 2022-10-01
EP4103179A1 (en) 2022-12-21
CN115103676A (zh) 2022-09-23
JP2023518670A (ja) 2023-05-08
WO2021161319A8 (en) 2021-10-07
AU2021219072A1 (en) 2022-09-22
EP4103179A4 (en) 2024-03-13
WO2021161319A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
HK1085390A1 (en) Solution for ungual and peri-ungual application and its use in preparation of a medicament treating dermatological diseases
NZ600000A (en) Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
BRPI0817804A8 (pt) Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
NZ599265A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
MX2022010006A (es) Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo.
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
PT1677806E (pt) Métodos para tratamento de entorse e distensão muscular aguda e por excesso de esforço utilizando ácido hialurónico
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
Wach et al. Severe erythema anulare centrifugum-like psoriatic drug eruption induced by terbinafine
MX2021015228A (es) Metodos y composiciones para mejorar resultados de pacientes con cancer.
MX2022009081A (es) Absorcion celular.
MX2022012967A (es) Tratamiento de la hidradenitis supurativa.
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
MX2022015146A (es) Tratamiento de la artritis reumatoide.
EP4151210A3 (en) Pyridine-carboline derivatives as mchr1 antagonists for use in therapy
MX2022016183A (es) Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina.
WO2020139163A3 (ru) Комбинация противовирусных средств
WO2023019095A3 (en) Momelotinib combination therapy
WO2021233571A8 (de) Behandlungsmittel zur antiviralen therapie, applikator und verfahren zur herstellung eines behandlungsmittels
MX2022009914A (es) El acido margarico disminuye el dolor mediado por piez02.
MX2023005899A (es) Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol.